PVLA

Palvella Therapeutics Inc

146.15

Oct 30 • 3:59 PM ET -5.43 (-3.58%)

148.00

Aftermarket • 7:30 PM ET +1.85 (1.27%)

Healthcare Biotechnology USA Mid NASD

Peers: KRYS ABEO ARQT MANE NVS ACRS INCY MIRM ORKA VRCA

| Held by: XBI VTI IWM VXF IWO SCHA VTWO VHT PTH DWAS

Scroll to Statements

Index	RUT
Market Cap	2.11B
Enterprise Value	1.88B
Income	-61.70M
Sales	0.00M
Book/sh	15.06
Cash/sh	17.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	29
IPO	Jan 02, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	9.70
P/C	8.40
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	21.18
Current Ratio	21.18
Debt/Eq	0.10
LT Debt/Eq	0.10
Option/Short	Yes / Yes

EPS (ttm)	-4.84
EPS next Y	-8.29
EPS next Q	-1.78
EPS this Y	-77.18%
EPS next Y	-26.08%
EPS next 5Y	-21.81%
EPS past 3/5Y	53.08% 41.62%
Sales past 3/5Y	- -
EPS Y/Y TTM	61.66%
Sales Y/Y TTM	-
EPS Q/Q	-77.78%
Sales Q/Q	-
Earnings	Nov 05 BMO
EPS/Sales Surpr.	-29.55% -

Insider Own	36.41%
Insider Trans	-1.52%
Inst Own	89.44%
Inst Trans	14.08%
ROA	-37.70%
ROE	-46.63%
ROIC	-25.78%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	11.43%
SMA50	3.31%
SMA200	15.14%
Trades

Shs Outstand	14.40M
Shs Float	9.16M
Short Float	26.28%
Short Ratio	11.35
Short Interest	2.41M
52W High	161.38 -9.44%
52W Low	71.55 104.26%
Volatility	6.38% 5.79%
ATR (14)	7.47
RSI (14)	59.55
Beta	-0.20
Rel Volume	1.38
Avg Volume	212.06K
Volume	293,067

Perf Week	16.83%
Perf Month	10.11%
Perf Quarter	3.81%
Perf Half Y	15.22%
Perf YTD	39.63%
Perf Year	86.37%
Perf 3Y	683.05%
Perf 5Y	-60.11%
Perf 10Y	20.19%
Recom	1.00
Target Price	227.88
Prev Close	151.58
Price	146.15
Change %	-3.58%

Consensus

Strong Buy

Avg. Price Target

$227.88

Implied Upside

+55.9%

Analysts16incl. previous ratings

Rating Distribution16 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 16, 2026	Initiated	WWilliam Blair	Outperform
Sep 21, 2026	Resumed	CChardan Capital Markets	Buy	$240	+64.2%
May 12, 2026	Initiated	SStephens	Overweight	$220	+50.5%
Jan 07, 2026	Initiated	MMizuho	Outperform	$205	+40.3%
Dec 05, 2025	Initiated	BBTIG Research	Buy	$167	+14.3%
Dec 04, 2025	Initiated	CCraig Hallum	Buy	$175	+19.7%
Nov 19, 2025	Upgrade	RRaymond James	Outperform → Strong Buy	$143	-2.2%
Sep 09, 2025	Initiated	OOppenheimer	Outperform	$85	-41.8%
Aug 06, 2025	Initiated	RRaymond James	Outperform	$54	-63.1%
Jul 21, 2025	Initiated	TTruist	Buy	$56	-61.7%
Apr 09, 2025	Initiated	CChardan Capital Markets	Buy	$50	-65.8%
Mar 26, 2025	Initiated	SStifel	Buy	$45	-69.2%
Mar 07, 2025	Initiated	BScotiabank	Sector Outperform	$50	-65.8%
Feb 20, 2025	Initiated	CCanaccord Genuity	Buy	$39	-73.3%
Feb 05, 2025	Initiated	TTD Cowen	Buy	$44	-69.9%
Dec 26, 2024	Initiated	HH.C. Wainwright	Buy	$38	-74.0%
Dec 18, 2024	Initiated	CCantor Fitzgerald	Overweight
Mar 13, 2020	Upgrade	RRobert W. Baird	Neutral → Outperform	$5	-96.6%
Jul 30, 2019	Downgrade	RRobert W. Baird	Outperform → Neutral
May 14, 2019	Initiated	RRobert W. Baird	Outperform	$5	-96.6%

Oct-29-26 11:59AM	Palvella's Q3 Report Hinges On NDA Completion Timing And Disciplined Launch Spending (Earnings Whispers)
07:30AM	Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026 (GlobeNewswire)
Oct-28-26 07:30AM	Palvella Announces FDA Acceptance and Priority Review of QTORIN Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set (GlobeNewswire) +10.95%
Oct-15-26 07:30AM	Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference (GlobeNewswire)
Oct-13-26 07:30AM	Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference (GlobeNewswire)
07:30AM	Loading…
Oct-12-26 07:30AM	Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026 (GlobeNewswire)
Sep-28-26 07:30AM	U.S. Food and Drug Administration Awards Additional Funding for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations (GlobeNewswire)
Sep-17-26 08:32AM	Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth (Business Wire)
Sep-09-26 07:30AM	Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer (GlobeNewswire)
Sep-02-26 07:30AM	Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-31-26 07:30AM	Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations (GlobeNewswire)
Aug-05-26 07:30AM	Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference (GlobeNewswire)
Aug-04-26 05:03PM	Palvella Therapeutics Inc (PVLA) (Q2 2026) Earnings Call Highlights: Strong Phase 3 Data and ... (GuruFocus.com) +7.96%
07:37AM	Palvella Therapeutics: Q2 Earnings Snapshot (Associated Press)
07:30AM	Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
07:30AM	Loading…
Jul-30-26 07:30AM	Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing (GlobeNewswire) +5.32%
Jul-28-26 07:30AM	Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 (GlobeNewswire)
Jul-22-26 10:34AM	What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity (FinanceWire)
Jun-30-26 07:30AM	Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors (GlobeNewswire)
Jun-29-26 07:30AM	Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations (GlobeNewswire)
Jun-22-26 08:49AM	Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy (InvestorsHub) +5.08%
07:30AM	FDA Grants Rolling Review of Palvella's QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations (GlobeNewswire)
Jun-03-26 07:30AM	Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN Rapamycin in Microcystic Lymphatic Malformations (GlobeNewswire) +10.27%
Jun-02-26 07:30AM	Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 (GlobeNewswire) -7.03%
May-27-26 07:30AM	Palvella Therapeutics Strengthens QTORIN Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 (GlobeNewswire)
May-21-26 07:30AM	Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards (GlobeNewswire)
May-20-26 04:30PM	Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations (GlobeNewswire) +5.77%
May-15-26 07:30AM	Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology (GlobeNewswire)
May-13-26 07:30AM	Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market (GlobeNewswire)
May-07-26 07:43AM	Palvella Therapeutics: Q1 Earnings Snapshot (Associated Press) -12.99%
07:30AM	Loading…
07:30AM	Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-26 07:30AM	Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN Rapamycin for Clinically Significant Angiokeratomas (GlobeNewswire)
Apr-30-26 07:30AM	Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 (GlobeNewswire)
Apr-22-26 06:03PM	Inventiva Builds Up Leadership Team Ahead of Potential Commercialization (Exec Edge)
Apr-20-26 07:30AM	Palvella Therapeutics to Present QTORIN Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 (GlobeNewswire)
Apr-13-26 07:30AM	Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors (GlobeNewswire)
Apr-07-26 07:30AM	Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales (GlobeNewswire)
Mar-31-26 03:02PM	Palvella Therapeutics Inc (PVLA) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) +12.64%
07:37AM	Palvella Therapeutics: Q4 Earnings Snapshot (Associated Press)
07:30AM	Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-30-26 07:30AM	Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations (GlobeNewswire)
Mar-27-26 10:30AM	Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-24-26 07:30AM	Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 (GlobeNewswire)
Mar-23-26 07:30AM	Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services (GlobeNewswire)
Mar-16-26 07:30AM	Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin (GlobeNewswire)
Mar-10-26 07:30AM	Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations (GlobeNewswire)
Mar-02-26 07:30AM	Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-25-26 07:57PM	Palvella Therapeutics Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.80% +15.35%
10:10AM	Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright (TipRanks)
Feb-24-26 08:07PM	Palvella Therapeutics Shares Jump as Phase 3 SELVA Trial Hits Primary Endpoint for QTORIN Rapamycin (MarketBeat) +37.08%
04:08PM	Why Top 2% Palvella Therapeutics, Up 33%, Just Blew Past Its 50-Day Line (Investor's Business Daily)
04:05PM	Palvella Therapeutics Announces Proposed Public Offering (GlobeNewswire)
11:10AM	Stocks Rally as AI-Fueled Worries Ease (Barchart)
10:15AM	Palvella Therapeutics (PVLA) Surges On Positive Phase 3 QTORIN SELVA Data (Benzinga)
09:59AM	Stocks Rebound as Software Stocks Recover (Barchart)
09:32AM	Why Top 2% Palvella Therapeutics Is About To Blow Past Its 50-Day Line (Investor's Business Daily)
06:30AM	Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations (GlobeNewswire)
06:00AM	Novo to cut GLP-1 drug prices; Palvella soars on study data (BioPharma Dive)
Feb-23-26 05:00PM	Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations (GlobeNewswire)
Feb-02-26 07:30AM	Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis (GlobeNewswire)
Jan-09-26 07:30AM	Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies (GlobeNewswire) -5.10%
Jan-07-26 09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly) +11.72%
07:30AM	Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs (GlobeNewswire)
Dec-21-25 07:31AM	High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin (Insider Monkey)
Dec-16-25 10:40AM	Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer (TipRanks) +8.80%
07:30AM	Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Angiokeratomas (GlobeNewswire)
Dec-15-25 06:00AM	Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies (GlobeNewswire) -9.74%
Nov-24-25 11:05AM	The Short-Sellers May Be Right About This Red-Hot Pharma Stock (Barchart)
Nov-11-25 04:01PM	Palvella Therapeutics Inc (PVLA) Q3 2025 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
07:37AM	Palvella Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-25 07:30AM	Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference (GlobeNewswire)
Nov-05-25 06:00AM	Palvella Therapeutics Announces New QTORIN Product Candidate, QTORIN Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies (GlobeNewswire)
Nov-04-25 07:30AM	Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025 (GlobeNewswire)
Oct-13-25 07:30AM	U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations (GlobeNewswire) +9.04%
Sep-24-25 06:00AM	Palvella Therapeutics Announces Expansion of QTORIN Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies (GlobeNewswire)
Sep-17-25 07:30AM	Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy (GlobeNewswire)
Sep-15-25 07:30AM	Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN Rapamycin for Cutaneous Venous Malformations (GlobeNewswire)
Sep-03-25 07:30AM	Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer (GlobeNewswire)
Aug-28-25 07:30AM	Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) -9.12%
Aug-14-25 07:35AM	Palvella Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 07:30AM	Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025 (GlobeNewswire)
Aug-06-25 09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 07:30AM	Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-09-25 07:20AM	Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin (Insider Monkey)
Jun-30-25 07:30AM	Palvella Therapeutics Added to Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-23-25 07:30AM	Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% (GlobeNewswire)
Jun-18-25 07:30AM	Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors (GlobeNewswire)
Jun-09-25 07:30AM	Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations (GlobeNewswire)
May-27-25 08:00AM	Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer (GlobeNewswire)
May-16-25 03:09AM	Palvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ... (GuruFocus.com)
May-15-25 07:30AM	Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-25 07:30AM	Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
May-05-25 07:30AM	Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 (GlobeNewswire)
Apr-30-25 05:44AM	Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025 (Insider Monkey)
Apr-23-25 04:15PM	Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology (GlobeNewswire)
Apr-22-25 07:30AM	Palvella Therapeutics Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations (GlobeNewswire) +5.74%
Apr-11-25 07:30AM	Palvella Therapeutics Announces QTORIN Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology (GlobeNewswire) +9.51%
Apr-04-25 08:00AM	Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goin Kathleen	Chief Operating Officer	Oct 21 '26	Option Exercise	8.11	4,313	34,962	4,313	Oct 23 04:05 PM
Goin Kathleen	Chief Operating Officer	Oct 21 '26	Sale	124.58	4,313	537,307	0	Oct 23 04:05 PM
Goin Kathleen	Officer	Oct 21 '26	Proposed Sale	123.92	4,313	534,467		Oct 21 04:21 PM
JENKINS GEORGE M	Director	Oct 12 '26	Sale	133.69	13,152	1,758,330	146,964	Oct 14 07:14 PM
JENKINS GEORGE M	Director	Oct 13 '26	Sale	130.36	7,174	935,232	139,790	Oct 14 07:14 PM
JENKINS GEORGE M	Director	Oct 14 '26	Sale	123.49	7,174	885,914	132,616	Oct 14 07:14 PM
JENKINS GEORGE M	Director	Oct 13 '26	Proposed Sale	134.38	27,500	3,695,450		Oct 13 04:59 PM
Goin Kathleen	Chief Operating Officer	Sep 16 '26	Option Exercise	8.11	4,302	34,883	4,302	Sep 18 04:05 PM
Goin Kathleen	Chief Operating Officer	Sep 16 '26	Sale	152.24	4,302	654,923	0	Sep 18 04:05 PM
Goin Kathleen	Officer	Sep 16 '26	Proposed Sale	151.22	4,302	650,548		Sep 16 04:31 PM
JENKINS GEORGE M	Director	Sep 14 '26	Sale	151.96	13,352	2,028,905	161,893	Sep 15 09:15 PM
JENKINS GEORGE M	Director	Sep 11 '26	Sale	151.28	12,371	1,871,435	175,245	Sep 15 09:15 PM
JENKINS GEORGE M	Director	Sep 15 '26	Sale	150.14	1,777	266,806	160,116	Sep 15 09:15 PM
JENKINS GEORGE M	Director	Sep 11 '26	Proposed Sale	150.39	27,500	4,135,725		Sep 11 04:34 PM
KIRITSY CHRISTOPHER P	Director	Sep 02 '26	Option Exercise	127.20	313	39,814	563	Sep 04 04:05 PM
KIRITSY CHRISTOPHER P	Director	Sep 02 '26	Sale	157.00	313	49,141	250	Sep 04 04:05 PM
CHRISTOPHER KIRITSY	Director	Sep 02 '26	Proposed Sale	157.00	375	58,875		Sep 02 04:10 PM
Goin Kathleen	Chief Operating Officer	Aug 19 '26	Option Exercise	8.11	4,302	34,883	4,302	Aug 20 04:05 PM
Goin Kathleen	Chief Operating Officer	Aug 19 '26	Sale	152.21	4,302	654,791	0	Aug 20 04:05 PM
Goin Kathleen	Officer	Aug 19 '26	Proposed Sale	150.42	4,302	647,107		Aug 19 04:56 PM
Goin Kathleen	Chief Operating Officer	Jul 15 '26	Option Exercise	8.11	4,302	34,883	4,302	Jul 17 04:05 PM
Goin Kathleen	Chief Operating Officer	Jul 15 '26	Sale	149.28	4,302	642,191	0	Jul 17 04:05 PM
Goin Kathleen	Officer	Jul 15 '26	Proposed Sale	149.68	4,302	643,923		Jul 15 04:20 PM
Goin Kathleen	Chief Operating Officer	Jun 17 '26	Option Exercise	8.11	4,302	34,883	4,302	Jun 22 05:06 PM
Goin Kathleen	Chief Operating Officer	Jun 17 '26	Sale	110.73	4,302	476,373	0	Jun 22 05:06 PM
Goin Kathleen	Officer	Jun 17 '26	Proposed Sale	110.73	4,302	476,373		Jun 17 05:11 PM
Korenberg Matthew E	CFO, Treasurer	Jun 12 '26	Option Exercise	13.60	1,000	13,600	1,000	Jun 16 04:05 PM
Goin Kathleen	Chief Operating Officer	May 20 '26	Option Exercise	8.11	4,302	34,883	4,302	May 22 04:05 PM
Goin Kathleen	Chief Operating Officer	May 20 '26	Sale	110.56	4,302	475,631	0	May 22 04:05 PM
Goin Kathleen	Officer	May 20 '26	Proposed Sale	110.56	4,302	475,631		May 20 05:47 PM
Goin Kathleen	Chief Operating Officer	Apr 15 '26	Option Exercise	8.11	4,302	34,883	4,302	Apr 17 04:05 PM
Goin Kathleen	Chief Operating Officer	Apr 15 '26	Sale	127.24	4,302	547,399	0	Apr 17 04:05 PM
Goin Kathleen	Officer	Apr 15 '26	Proposed Sale	129.53	4,302	557,238		Apr 15 04:00 PM
JENKINS GEORGE M	Director	Mar 30 '26	Buy	112.30	445	49,974	187,616	Apr 01 04:05 PM
Goin Kathleen	Chief Operating Officer	Mar 18 '26	Option Exercise	8.11	4,302	34,883	4,302	Mar 20 04:05 PM
Goin Kathleen	Chief Operating Officer	Mar 18 '26	Sale	117.99	4,302	507,611	0	Mar 20 04:05 PM
Goin Kathleen	Officer	Mar 18 '26	Proposed Sale	120.80	4,302	519,681		Mar 18 04:01 PM
JENKINS GEORGE M	Director	Feb 27 '26	Buy	125.00	4,000	500,000	187,171	Mar 02 08:00 AM
HERON ELAINE J	Director	Feb 27 '26	Buy	125.00	2,400	300,000	47,812	Mar 02 08:00 AM
Goin Kathleen	Chief Operating Officer	Feb 18 '26	Option Exercise	8.11	4,302	34,883	4,302	Feb 20 04:05 PM
Goin Kathleen	Chief Operating Officer	Feb 18 '26	Sale	79.40	4,302	341,564	0	Feb 20 04:05 PM
Goin Kathleen	Officer	Feb 18 '26	Proposed Sale	80.09	4,301	344,467		Feb 18 03:59 PM
Goin Kathleen	Chief Operating Officer	Jan 21 '26	Option Exercise	8.11	4,302	34,883	4,302	Jan 23 04:05 PM
Goin Kathleen	Chief Operating Officer	Jan 21 '26	Sale	97.63	4,302	419,983	0	Jan 23 04:05 PM
Goin Kathleen	Officer	Jan 21 '26	Proposed Sale	98.01	4,302	421,639		Jan 21 04:33 PM
Goin Kathleen	Chief Operating Officer	Dec 17 '25	Option Exercise	8.11	4,302	34,883	4,302	Dec 19 04:05 PM
Goin Kathleen	Chief Operating Officer	Dec 17 '25	Sale	96.47	4,302	415,023	0	Dec 19 04:05 PM
Goin Kathleen	Officer	Dec 17 '25	Proposed Sale	96.81	4,302	416,477		Dec 17 04:33 PM
Goin Kathleen	Chief Operating Officer	Nov 19 '25	Option Exercise	8.11	4,302	34,883	4,302	Nov 21 04:25 PM
Goin Kathleen	Chief Operating Officer	Nov 19 '25	Sale	86.23	4,302	370,965	0	Nov 21 04:25 PM
Goin Kathleen	Officer	Nov 19 '25	Proposed Sale	82.94	4,302	356,808		Nov 19 04:46 PM

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

FounderMr. Wesley H. Kaupinen

CFOMr. Matthew E. Korenberg

Chief Operating OfficerMs. Kathleen Goin

Chief Scientific OfficerDr. Jeffrey Martini Ph.D.

Vice President of Investor Relations & Corporate AffairsMs. Marcy B. Nanus

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PVLA

Palvella Therapeutics Inc

Upgrade your Finviz experience